Welgene Biotech Co.,Ltd. (TPEX:6661)

Welgene Biotech Revenue

Welgene Biotech had revenue of 107.21M TWD in the quarter ending June 30, 2026, with 18.98% growth. This brings the company's total for the last twelve months to 398.92M, up 15.25% year-over-year. In the year 2025, Welgene Biotech had annual revenue of 375.94M with 16.55% growth. That makes Welgene Biotech the 36,492nd largest company in the world by revenue and 1,910th in Taiwan.

• Revenue (ttm): 398.92M
• Revenue Growth: +15.25%
• P/S Ratio: 0.94
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 376.36M

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Biotechnology Testing Department 306.99M 81.7%
• Instrument Sales Department 68.95M 18.3%

Fiscal year ended Dec 31, 2025 See the full Welgene Biotech breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	375.94M	53.39M	16.55%
Dec 31, 2024	322.55M	42.00M	14.97%
Dec 31, 2023	280.55M	-41.35M	-12.85%
Dec 31, 2022	321.90M	9.25M	2.96%
Dec 31, 2021	312.65M	-85.45M	-21.46%

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 4, 2026

Data Sources Report a data error